Pseudomyxoma Peritonei (PMP): Causes, Spread, and HIPEC

Pseudomyxoma peritonei, often shortened to PMP, is a rare condition in which the abdominal cavity slowly fills with a jelly-like mucin produced by tumor cells. In most cases, the process starts with a small mucinous tumor in the appendix that ruptures and seeds the peritoneal lining with mucin-producing cells.¹ Because symptoms tend to be vague and the condition is unfamiliar to many doctors, PMP is frequently discovered by accident during surgery for something else. What follows is a guide to how this disease behaves, how it is diagnosed and graded, what treatment looks like, and what to realistically expect afterward.

Where Does It Come From

The overwhelming majority of PMP cases trace back to the appendix. A mucinous neoplasm forms in the appendiceal wall, eventually perforates, and releases mucin-secreting cells into the peritoneal cavity. The appendiceal origin was not always appreciated. For decades, the condition was attributed to ovarian tumors, largely because PMP was first described in a woman thought to have a ruptured ovarian cyst.² Modern immunohistochemistry and molecular analysis have shown that most supposed ovarian primaries are actually metastases from an appendiceal tumor that was missed on initial workup.³

Non-appendiceal origins do exist but are uncommon. In one comparative study, about 8% of PMP patients had a primary site outside the appendix, including the ovary, uterine cervix, and mature cystic teratomas.⁴ A separate study of 310 PMP patients found ovarian origin in fewer than 3% of cases.⁵ The practical takeaway: if you are told you have PMP, the appendix is the prime suspect even when no obvious appendiceal mass is initially seen on imaging.

How PMP Spreads Inside the Abdomen

PMP does not spread through the bloodstream or lymph nodes the way most cancers do. Instead, mucin and tumor cells drift through the peritoneal fluid, settling in predictable places governed by gravity and the body’s own fluid-circulation patterns. This behavior is called the “redistribution phenomenon.”⁶ Mucin pools at sites where peritoneal fluid is naturally reabsorbed: the greater and lesser omentum (the fatty aprons that drape over the intestines), the undersurface of the diaphragm (especially on the right side), and other dependent areas of the pelvis.⁷

The mobile small bowel tends to be relatively spared early on, because its constant motion prevents mucin from sticking and because mucin-producing cells preferentially accumulate in more stationary areas. Over time, however, mucin builds up enough to compress organs, obstruct the bowel, and impair nutrition. Left untreated, this progressive accumulation is what eventually becomes life-threatening. The disease is slow-growing in most cases, which is both a blessing (it buys time) and a curse (symptoms may not trigger investigation until the disease is advanced).

Grading and Classification

Not all PMP behaves the same way. A key international effort by the Peritoneal Surface Oncology Group International (PSOGI) established a consensus classification that divides PMP into three grades: low-grade, high-grade, and high-grade with signet ring cells. Acellular mucin, meaning mucin deposits that contain no identifiable tumor cells, is classified separately.⁸

The distinction matters enormously for prognosis. In a study of 57 patients, those with low-grade PMP had a five-year survival of about 56%, while high-grade patients had about 38% and those with signet ring cells had roughly 25%.⁹ A larger validation study of 265 patients confirmed that the PSOGI grading system independently predicts outcomes.¹⁰ The grade is determined by a pathologist examining tissue samples, so accurate grading depends on obtaining adequate biopsies during surgery or diagnostic procedures.

The Genetic Fingerprint

Two gene mutations turn up with striking consistency in PMP tissue. KRAS and GNAS are both involved in cell growth signaling, and they are found together in the majority of PMP tumors. One study found the two mutations co-occurred in about 78% of cases.¹¹ Another analysis of 25 PMP samples detected KRAS mutations in 84% and found that both genes were mutated together in 20 of 25 cases.¹²

These mutations are not just diagnostic curiosities. The dominance of GNAS mutations in PMP, relatively unusual in other cancers, opens the door to targeted therapies. A peptide vaccine aimed at mutant GNAS has been explored in early research, based on the logic that almost all PMP patients carry the mutation and the immune system could be trained to attack cells expressing the abnormal protein.¹³ At the molecular level, PMP tumors also massively overproduce gel-forming mucins, particularly MUC2 and MUC5AC, which are the molecules responsible for the characteristic jelly-like material that fills the abdomen.¹⁴

How PMP Is Detected

PMP is often found incidentally during imaging or surgery performed for other reasons, such as a suspected appendicitis, hernia repair, or investigation of new-onset abdominal swelling. On CT scans, the most common findings are peritoneal and omental nodules (sometimes described as “omental caking”), followed by a distinctive pattern called visceral scalloping, where the mucin presses against the edges of solid organs like the liver and spleen, creating indentations on their surfaces.¹⁵

Liver scalloping in particular has prognostic significance. One study found it in about 63% of PMP patients on CT, and those with scalloping had significantly shorter disease-free survival after surgery compared to those without it.¹⁶ A separate analysis confirmed that scalloping on both the liver and spleen was associated with a lower chance of achieving complete surgical removal of the disease.¹⁷ In other words, the CT appearance gives surgeons advance warning about how difficult the operation will be and how likely recurrence is.

Blood tests for tumor markers like CEA, CA19-9, and CA-125 can support the diagnosis but are not definitive on their own. The markers tend to be more informative when measured in ascites fluid (the liquid that accumulates in the abdomen) rather than in blood. In one study, the sensitivity of ascites CEA for diagnosing appendiceal PMP was about 84%.¹⁸ Definitive diagnosis still requires tissue sampling and pathological examination.

The Standard Treatment

The cornerstone treatment for PMP is cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC). CRS involves physically removing all visible tumor and mucin from the abdominal cavity, which can mean stripping the peritoneal lining, removing the omentum, and sometimes resecting portions of affected organs. Immediately after, heated chemotherapy is circulated directly through the abdomen for a period of time, intended to kill any microscopic tumor cells that surgery missed.¹⁹

The completeness of cytoreduction is one of the single most important predictors of long-term outcome. Surgeons score how much residual disease is left behind, and patients who achieve a complete or near-complete removal consistently do better than those with significant residual tumor.²⁰ The specific chemotherapy drugs used during HIPEC have varied over time. One large analysis found that the combination of cisplatin and mitomycin was associated with a reduction in the risk of death compared to other regimens, building on evidence that mitomycin enhances the effect of cisplatin inside cells.²¹

Risks of CRS and HIPEC

This is a big operation, often lasting many hours, and it carries real risks. A large Italian registry found an overall complication rate of 34% and a mortality rate of about 1.6%. Around 9% of patients needed a second operation to manage surgical complications.²² A Japanese center reported a somewhat higher complication rate of 49%, with a 30-day mortality of about 3.5%.²³ These numbers reflect all peritoneal surface malignancies treated with CRS/HIPEC, not only PMP.

For context, the complication rates do not appear to be dramatically different from those of other extensive abdominal surgeries, and the HIPEC component itself seems to contribute relatively little additional risk beyond what the surgery alone imposes.²⁴ The major drivers of complications are how many organs need to be resected, the patient’s body mass index, and age. The number of organ resections and age were the strongest predictors of mortality.²⁵

Survival and Recurrence

With CRS and HIPEC at experienced centers, the survival numbers for PMP are among the better outcomes in peritoneal cancers, though the disease is persistent and recurrence is common. A large study of 2,298 patients reported a median survival of about 16 years, with 10-year and 15-year survival rates of 63% and 59%.²⁶ These are impressive figures for a peritoneal malignancy, and they largely reflect patients with low-grade disease who had complete tumor removal.

The flip side is that recurrence is the rule rather than the exception. Even when surgeons achieve complete cytoreduction, disease came back in about 91% of patients in one long-term analysis, with a median disease-free interval of two years.²⁷ This does not necessarily mean those patients die of the disease quickly. In a study of 512 patients, about 26% developed recurrence, and those who underwent repeat surgery had five-year survival of 79%, while those who recurred but did not have repeat surgery had five-year survival of about 65%.²⁸ Repeat CRS for recurrence is feasible and carries complication rates comparable to the first operation.

The strongest predictors of long-term survival are histological grade (low-grade does far better than high-grade) and completeness of cytoreduction.²⁹ Ten-year survivors overwhelmingly have low-grade pathology. For patients with high-grade or signet ring cell features, the prognosis is considerably worse, and the approach to treatment may involve systemic chemotherapy in addition to or instead of surgical intervention.

Quality of Life After Treatment

Given the scale of the surgery, one of the first questions patients ask is: what will life look like afterward? Prospective studies tracking quality of life tell a nuanced story. In the first weeks and months, patients experience substantial declines in physical function, energy, and overall well-being. Pain, fatigue, appetite loss, and sleep disturbance all peak in the early postoperative period.³⁰

The encouraging finding is that most functional measures return to baseline by about 12 months. Global quality-of-life scores in one prospective study were essentially back to preoperative levels by one year.³¹ Another longitudinal study found that physical, role, and social function scores no longer differed from the general population after 12 months. However, certain symptoms lingered longer: persistent changes in bowel habits (constipation and diarrhea) and mild cognitive effects were measurable beyond the one-year mark in some patients.³² These lingering bowel symptoms are not surprising given that the surgery often involves peritoneal stripping near the intestines and sometimes partial bowel resection.

Systemic Chemotherapy and When It Is Used

CRS/HIPEC is the primary treatment, but not every patient is a candidate. Some patients have disease that is too extensive for complete surgical removal, or they have medical conditions that make a major operation too dangerous. For these patients, systemic (intravenous) chemotherapy becomes the main option, though the evidence base is thinner than for surgery. Fluoropyrimidine-based regimens are the most commonly used. One study evaluating modified FOLFOX6 (a combination of fluorouracil, leucovorin, and oxaliplatin) in patients with unresectable PMP found it to be a tolerable option that showed some effectiveness.³³

The honest reality is that systemic chemotherapy for PMP remains somewhat disappointing. The mucin-rich, slow-growing nature of most PMP tumors makes them relatively resistant to conventional chemotherapy drugs, which tend to work best against rapidly dividing cells. This is one reason researchers have been hunting for alternative approaches.

Experimental and Emerging Therapies

Two emerging approaches have attracted particular interest. The first is BromAc, a combination of bromelain (an enzyme from pineapple) and acetylcysteine (the same drug used to treat acetaminophen overdoses). The logic is straightforward: if the mucin itself is a major part of the problem, dissolving it could improve outcomes. A phase I trial found that injecting BromAc directly into the peritoneal cavity produced considerable mucin breakdown, both by the volume of mucin drained and by changes visible on imaging.³⁴ This is still in early stages, but the concept of targeting the mucin rather than (or in addition to) the tumor cells is a genuinely different strategy from conventional chemotherapy.

The second is pressurized intraperitoneal aerosol chemotherapy, or PIPAC, which delivers chemotherapy as a fine mist under pressure during a minimally invasive (laparoscopic) procedure. A case report documented clinical and histological disease remission in a woman with PMP treated with PIPAC using cisplatin and doxorubicin.³⁵ PIPAC is appealing because it can be repeated multiple times with relatively low morbidity, potentially making it suitable for patients who cannot tolerate a full CRS/HIPEC. Both BromAc and PIPAC are still being studied, and neither has replaced CRS/HIPEC as the standard of care.³⁶

Why Where You Get Treated Matters

CRS/HIPEC is not a procedure that every hospital offers, and the evidence strongly suggests that center volume affects outcomes. A study analyzing results across multiple institutions found that centers performing at least 45 CRS/HIPEC procedures per year had significantly lower 90-day postoperative morbidity compared to lower-volume centers. Perhaps more strikingly, high-volume centers had lower “failure-to-rescue” rates, meaning that when complications did arise, they were more successfully managed, even though these centers took on more extensive cases.³⁷

For patients diagnosed with PMP, this is one of the most actionable pieces of information in the entire disease landscape. Seeking out a specialized peritoneal malignancy center, even if it means traveling, can materially affect not just surgical outcomes but long-term survival. Many countries have centralized these procedures to a handful of expert centers for exactly this reason. Patient advocacy organizations specific to PMP and appendiceal cancer can help connect newly diagnosed patients with appropriate specialists, which matters in a disease rare enough that many general oncologists will see only one or two cases in a career.

The Ovarian Misattribution Problem

One misconception worth understanding, particularly for women, is the historical confusion between PMP and ovarian cancer. When PMP spreads through the pelvis, it can coat the ovaries with mucinous tumor deposits, making it look for all the world like the disease started there. For decades, many women with PMP were diagnosed with and treated for primary ovarian cancer. Molecular studies have since demonstrated that in most of these cases, the ovarian masses are secondary deposits from an appendiceal primary.³⁸ True primary ovarian PMP exists but is genuinely rare.

This distinction is not academic. The treatment for PMP is different from the treatment for ovarian cancer: PMP calls for CRS/HIPEC at a specialized center, while ovarian cancer is treated with a different surgical approach and different chemotherapy regimens. A misdiagnosis can lead to years of suboptimal treatment. If a woman is diagnosed with “mucinous ovarian cancer” and the pathology shows mucinous peritoneal deposits, it is worth asking whether the appendix has been properly evaluated as a possible source. Immunohistochemical staining patterns and molecular profiling can usually settle the question.³⁹